Back

QT prolongation in cardio-oncology: understanding the risk

19 June 2026 (08:50 - 09:00)
Organised by: Logo
Congress Presentation Part of: Cardio-onco pharmacology: expanding the multidisciplinary team and facing new challenges Cardio-Oncology CCO Premium Access ESC Cardio-Oncology 2026 Council of Cardio-Oncology

About the speaker

Photo
Doctor Michael Fradley

Hospital of the University of Pennsylvania, Philadelphia (United States of America)

3 More presentations in this session

Presentation thumbnail
General principles of drug–drug interactions in cardio-oncology
Doctor B. Aretin (Vienna, AT)
Slides
Presentation thumbnail
How to report cardiovascular side effects: practical guidance
Doctor C. Dolladille (Caen, FR)
Slides
Presentation thumbnail
Cardio-Onco Pharmacology: expanding the multidisciplinary team and facing new challenges - discussion

Access the full session

Session thumbnail
Cardio-onco pharmacology: expanding the multidisciplinary team and facing new challenges
Video

The Event

Event poster

ESC Cardio-Oncology 2026

19 June 2026 08:50 CET
You may be interested in
thumbnail
Webinar
Council Webinar: How, when and why advanced cardiac echo is needed in cardio oncology?
27 January 2020
thumbnail
Congress Presentation
Incidence of drug-drug interactions of QT-prolonging drugs in an onco-hematological outpatient
27 August 2022
thumbnail
Congress Presentation
Cancer drug-induced QT prolongation: what to do?
21 June 2025
thumbnail
Webinar
Current role of cardiovascular pharmacotherapy for arrhythmia management
9 December 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources